HC Wainwright & Co. Maintains Buy on BridgeBio Pharma, Lowers Price Target to $22
HC Wainwright & Co. maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and lowers the price target from $24 to $22.
BridgeBio Pharma Posts Updated Data From Muscular Dystrophy Trial, Plots Path To Market
BridgeBio Pharma Inc (NASDAQ: BBIO) has
BridgeBio Pharma Announces ‘Positive’ Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i
- 43% increase in the ratio of glycosylated alpha-dystroglycan (αDG) to total αDG from baseline were measured across all three dosing cohorts, signifying the oral therapy has the potential to
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb’s Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.
SVB Leerink Maintains Outperform on BridgeBio Pharma, Raises Price Target to $26
SVB Leerink analyst Mani Foroohar maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises the price target from $25 to $26.
BridgeBio Pharma And Sentynl Therapeutics Announce Asset Purchase Agreement For BridgeBio Pharma’s NULIBRY
BridgeBio Pharma, Inc. (NASDAQ:BBIO) (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, and Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical
Helsinn, BridgeBio Pharma Amend Infigratinib Pact For Oncology Indications
Helsinn Group and BridgeBio Pharma Inc (NASDAQ: BBIO) have
Helsinn Group And BridgeBio Pharma Announce Update To Infigratinib Collaboration In US; Helsinn Will Gain Exclusive License To Commercialize Infigratinib I US
Helsinn Group and BridgeBio Pharma Announce Update to Strategic Collaboration to Develop, Manufacture and Commercialize Infigratinib in Oncology Indications in the U.S.
Helsinn gains an exclusive license to
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's trading, 505 companies set new 52-week lows.
